Gilead SciencesGILDEarnings & Financial Report
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
GILD Q3 2025 Key Financial Metrics
Revenue
$7.8B
Gross Profit
$6.2B
Operating Profit
$3.3B
Net Profit
$3.1B
Gross Margin
79.8%
Operating Margin
42.8%
Net Margin
39.3%
YoY Growth
3.0%
EPS
$2.43
Financial Flow
Gilead Sciences Q3 2025 Financial Summary
Gilead Sciences reported revenue of $7.8B for Q3 2025, with a net profit of $3.1B (39.3% margin). Cost of goods sold was $1.6B, operating expenses totaled $2.9B.
Key Financial Metrics
| Total Revenue | $7.8B |
|---|---|
| Net Profit | $3.1B |
| Gross Margin | 79.8% |
| Operating Margin | 42.8% |
| Report Period | Q3 2025 |
Gilead Sciences Annual Revenue by Year
Gilead Sciences annual revenue history includes year-by-year totals (for example, 2024 revenue was $28.8B).
| Year | Annual Revenue |
|---|---|
| 2024 | $28.8B |
| 2023 | $27.1B |
| 2022 | $27.3B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.11B | $6.69B | $6.95B | $7.54B | $7.57B | $6.67B | $7.08B | $7.77B |
| YoY Growth | -3.7% | 5.3% | 5.4% | 7.0% | 6.4% | -0.3% | 1.8% | 3.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $62.13B | $56.29B | $53.58B | $54.52B | $58.99B | $56.43B | $55.72B | $58.53B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $22.83B | $17.54B | $18.28B | $18.48B | $19.33B | $19.16B | $19.67B | $21.54B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.17B | $2.22B | $1.32B | $4.31B | $2.98B | $1.76B | $827.0M | $4.11B |
Other Health Care Companies
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
AMGN
Amgen
Revenue
$9.9B
Net Profit
$1.3B
BIIB
Biogen
Revenue
$2.3B
Net Profit
$-48.9M
INCY
Incyte
Revenue
$1.5B
Net Profit
$299.3M
MRNA
Moderna
Revenue
$1.0B
Net Profit
$-200.0M
REGN
Regeneron Pharmaceuticals
Revenue
$3.9B
Net Profit
$844.6M
VRTX
Vertex Pharmaceuticals
Revenue
$3.2B
Net Profit
$1.2B
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M